Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.
|Articles|February 23, 2012
CHIME Wants Minimal Delay on ICD-10
Advertisement
Another health information technology group pushed back on the recent HHS decision to indefinitely delay implementation of ICD-10. The College of Healthcare Information Management Executives warned against a long delay in the deadline for healthcare organizations to switch over to what is called the ICD-10 family of diagnostic and procedural codes from ICD-9, according to a letter (PDF) to HHS Secretary Kathleen Sebelius.
That warning followed HHS' Feb. 16 announcement that it was pushing back its Oct. 1, 2013 deadline for ICD-10 implementation to an as yet undetermined future date.
Read the full story:
Source: ModernHealthcare.com
Advertisement
Related to this article
CDC's Jane Henley, MSPH, explains what's behind falling lung cancer deaths and why 4 in 5 eligible adults still aren't getting screened.
The regulatory decisions reflect how advances in biomarkers and molecular medicine are reshaping both diagnosis and treatment.
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Community oncologists cited prior authorization as a care barrier, even as AI adoption doubled in 2026, according to the Oncology Care Index.
A large propensity-matched study linked outpatient melatonin use to a small reduction in REM sleep in children evaluated for polysomnography.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Advertisement
Advertisement
Trending on AJMC
1
Peptide Regulation Debate Intensifies After FDA Advisory Panel's Controversial Vote
2
Health System Pharmacies Keep Patients on GLP-1 Therapy
3
Melatonin Use Linked to Small REM Sleep Reduction in Children
4
Medicare Part D Ruxolitinib Spending Hits $49.6 Million as Use Surges
5